NVUS - Novus Therapeutics, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue---
Cost of Revenue---
Gross Profit---
Operating Expenses
Research Development2,0223,19132,638
Selling General and Administrative11,0991,93712,623
Non Recurring---
Total Operating Expenses---
Operating Income or Loss-13,121-5,128-45,261
Income from Continuing Operations
Total Other Income/Expenses Net5-527174
Earnings Before Interest and Taxes-13,116-5,655-45,087
Interest Expense---
Income Before Tax-13,116-5,655-45,087
Income Tax Expense---
Minority Interest---
Net Income From Continuing Ops-13,116-5,655-45,087
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-13,116-5,655-45,087
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-13,116-5,655-45,087